OVERVIEW
The overall biomarkers market is expected to grow from to reach $59.85 billion by 2024, at a CAGR of 13.28% during the forecast period 2019-2024. The global biomarkers market is mainly driven by increasing diagnostic applications, and rising R&D funding for pharmaceutical and biotech companies. Additionally, increasing number of CROs and low cost of clinical trials in developing countries is also analyzed to drive the market.








TABLE OF CONTENT
1 Biomarkers Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope
2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
3 Biomarkers Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography
4 Biomarkers Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis
5 Biomarkers Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies
6 Biomarkers Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.1.1 Growing diagnostic applications of biomarkers
6.2.1.2 Increasing R&D funding for pharma companies
6.2.1.3 New initiatives for biomarker research
6.2.2 Restrain
6.2.2.1 High capital investments and low cost-benefit ratio
6.2.2.2 Issues in sample collection and storage
6.2.3 Challenges
6.2.3.1 Proving the Clinical Validity in Biomarker-Based Tests
6.2.4 Opportunities
6.2.4.1 Emerging Economies
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7 Biomarkers Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)
8 Biomarkers Market – By Type (Market Size – & million/billion)
8.1 Disease-related biomarkers
8.2 Drug-related biomarkers
8.3 Imaging biomarkers
8.4 Molecular biomarkers
8.5 Surrogate biomarkers
8.6 Others
9 Biomarkers Market – By Products
9.1 Hormones
9.2 Enzymes
9.3 Antibodies
9.4 Gene products
10 Biomarkers Market – By Application
10.1 Drug discovery & Development
10.2 Molecular diagnostics
10.3 Genetic studies
10.4 Clinical Trials
10.5 Bioinformatics
10.6 Others
11 Biomarkers Market – By End Use Industry
11.1 Pharmaceutical Companies
11.2 Hospitals
11.3 Research Institutes
11.4 CROs
11.5 Diagnostic Labs
12 Biomarkers Market – By Geography (Market Size – & million/billion)
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 U.K
12.3.2 Germany
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Rest of APAC
12.5 Rest of the World
12.5.1 South America
12.5.2 Middle East
12.5.3 Africa
13 Biomarkers Market – Entropy
13.1 New product launches
13.2 M&A’s, collaborations, JVs and partnerships
14 Biomarkers Market Company Profile (Key Players)
14.1 Market Share, Company Revenue, Products, M&A, Developments
14.2 Perkinelmer, Inc.
14.3 Enzo Biochem, Inc.
14.4 EKF Diagnostics Holdings, Inc.
14.5 Qiagen N.V.
14.6 Cisbio Bioassays
14.7 Signosis, Inc.
14.8 Merck Millipore
14.9 Meso Scale Diagnostics, LLC.
14.10 Biosims Technologies Sas
14.11 Bio-Rad Laboratories, Inc.
14.12 Company 11 & more
15 Biomarkers Market – Appendix
15.1 Sources
15.2 Abbreviations